Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure

Journal of the American Society of Nephrology

Volumn 17, Issue 11, 2006, Pages 3041-3048

  Michaud, Josée ^a,b   Naud, Judith ^a,b   Chouinard, Jérôme ^a   Désy, François ^a   Leblond, Francois A ^a   Desbiens, Karine ^a   Bonnardeaux, Alain ^a   Pichette, Vincent ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; HORMONE ANTIBODY; LIVER ENZYME; PARATHYROID HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG METABOLISM; HORMONAL REGULATION; LIVER CELL; MALE; NONHUMAN; PARATHYROIDECTOMY; PRIORITY JOURNAL; RAT; UREMIA;

EID: 33750723125     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006010035     Document Type: Article

References (50)

1. Matzke GE, Frey RF: Drug dosing in patients with impaired renal function. In: Pharmacotherapy: A Pathophysiologic Basis, 2nd Ed., edited by Pipiro JT TR, Hayes PE, Yee GC, Matzke GR, Posey ML, New York, Elsevier Science Publishing, 1992, pp 750-763
2. Matzke GR, Frye RF: Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 16: 205-231, 1997
3. Touchette MA, Slaughter RL: The effect of renal failure on hepatic drug clearance. DICP 25: 1214-1224, 1991
4. Gibson TP: Renal disease and drug metabolism: An overview. Am J Kidney Dis 8: 7-17, 1986
5. Pichette V, Leblond F: Metabolism of drugs in chronic renal failure. Recent Res Dev Drug Metab Dispos 1: 43-56, 2002
6. Pichette V, Leblond FA: Drug metabolism in chronic renal failure. Curr Drug Metab 4: 91-103, 2003
7. Uchida N, Kurata N, Shimada K, Nishimura Y, Yasuda K, Hashimoto M, Uchida E, Yasuhara H: Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 68: 431-439, 1995
8. Patterson SE, Cohn VH: Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol 33: 711-716, 1984
9. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001
10. Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V: Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13: 1579-1585, 2002
11. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V: Down-regulation of hepatic cytochrome P450 in chronic renal failure: Role of uremic mediators. Br J Pharmacol 137: 1039-1046, 2002
12. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144: 1067-1077, 2005
13. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44: 707-715, 1993
14. Levi R, Silver J: Pathogenesis of parathyroid dysfunction in end-stage kidney disease. Pediatr Nephrol 20: 342-345, 2005
15. Massry SG, Klin M, Ni Z, Tian J, Kedes L, Smogorzewski M: Impaired agonist-induced calcium signaling in hepatocytes from chronic renal failure rats. Kidney Int 48: 1324-1331, 1995
16. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG: Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone. J Clin Invest 97: 2167-2173, 1996
17. Qing DP, Ding H, Vadgama J, Wu YY, Kopple JD: Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 10: 84-92, 1999
18. Leblond FA, Giroux L, Villeneuve JP, Pichette V: Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28: 1317-1320, 2000
19. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X, Yao X, Ma D, Slungaard A, Hebbel RP, Key NS, Geng JG: Andrographalide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 173: 4207-4217, 2004
20. Munoz C, Pascual-Salcedo D, Castellanos MC, Alfranca A, Aragones J, Vara A, Redondo JM, de Landazuri MO: Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: Modulation of NF-kappa B and AP-1 transcription factors activity. Blood 88: 3482-3490, 1996
21. Tindberg N, Baldwin HA, Cross AJ, Ingelman-Sundberg M: Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol 50: 1065-1072, 1996
22. Cinti DL, Moldeus P, Schenkman JB: Kinetic parameters of drug-metabolizing enzymes in Ca2+-sedimented microsomes from rat liver. Biochem Pharmacol 21: 3249-3256, 1972
23. Nicoll-Griffith DA, Chauret N, Houle R, Day SH, D'Antoni M, Silva JM: Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes. Drug Metab Dispos 32: 1509-1515, 2004
24. Cantu TG, Ellerbeck EF, Yun SW, Castine SD, Kornhauser DM: Drug prescribing for patients with changing renal function. Am J Hosp Pharm 49: 2944-2948, 1992
25. Goltzman D, Hurdy G: Parathyroid hormone. In: Principles and Practice of Endocrinology and Metabolism, edited by Becker KL, Philadelphia, Lippincott, 1990, pp 402-411
26. Massry SG, Smogorzewski M: Parathyroid hormone, chronic renal failure and the liver. Kidney Int Suppl 62: S5-S7, 1997
27. Smogorzewski M, Massry SG: Defects in B-cell function and metabolism in uremia: Role of parathyroid hormone. Kidney Int Suppl 78: S186-S189, 2001
28. Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects. Am J Kidney Dis 38[Suppl 5]: S20-S33, 2001
29. Smogorzewski MJ: Central nervous dysfunction in uremia. Am J Kidney Dis 38[Suppl 1]: S122-128, 2001
30. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC: Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282: 1-17, 2002
31. Picotto G, Massheimer V, Boland R: Parathyroid hormone stimulates calcium influx and the cAMP messenger system in rat enterocytes. Am J Physiol 273: C1349-C1353, 1997
32. Jansson I, Curti M, Epstein PM, Peterson JA, Schenkman JB: Relationship between phosphorylation and cytochrome P450 destruction. Arch Biochem Biophys 283: 285-292, 1990
33. Pyerin W, Horn F, Taniguchi H: Posttranslational modifications of the cytochrome P-450 monooxygenase system. J Cancer Res Clin Oncol 113: 155-159, 1987
34. Sidhu JS, Omiecinski CJ: cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem 270: 12762-12773, 1995
35. Galisteo M, Marc N, Fautrel A, Guillouzo A, Corcos L, Lagadic-Gossmann D: Involvement of cyclic nucleotide- and calcium-regulated pathways in phenobarbital-induced cytochrome P-450 3A expression in mouse primary hepatocytes. J Pharmacol Exp Ther 290: 1270-1277, 1999
36. LeHoux JG, Dupuis G, Lefebvre A: Regulation of CYP11B2 gene expression by protein kinase C. Endocr Res 26: 1027-1031, 2000
37. Clyne CD, White PC, Rainey WE: Calcium regulates human CYP11B2 transcription. Endocr Res 22: 485-492, 1996
38. Graier WF, Simecek S, Sturek M: Cytochrome P450 monooxygenase-regulated signalling of Ca2+ entry in human and bovine endothelial cells. J Physiol (Lond) 482: 259-274, 1995
39. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734, 2002
40. Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA: Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274: 510-515, 1999
41. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y: Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276: 39638-39644, 2001
42. Ali NN, Gilston V, Winyard PG: Activation of NF-kappaB in human osteoblasts by stimulators of bone resorption. FEBS Lett 460: 315-320, 1999
43. Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P: Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem 277: 28109-28117, 2002
44. Bistrian BR: Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD. Am J Kidney Dis 32[Suppl 4]: S113-S117, 1998
45. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
46. Higuchi T, Yamamoto C, Kuno T, Mizuno M, Takahashi S, Kanmatsuse K: Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron 76: 26-31, 1997
47. Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H: In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10: 2244-2249, 1995
48. Oettinger CW, Bland LA, Oliver JC, Arduino MJ, McAllister SK, Favero MS: The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J Am Soc Nephrol 4: 1890-1895, 1994
49. Sunder-Plassmann G, Kapiotis S, Gasche C, Klaar U: Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int 45: 1484-1488, 1994
50. Ziesche R, Roth M, Papakonstantinou E, Nauck M, Horl WH, Kashgarian M, Block LH: A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 91: 301-305, 1994